Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma

Okuda, 2002, Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology, J Gastroenterol Hepatol, 17, 1049, 10.1046/j.1440-1746.2002.02781.x

Patel, 2001, Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States, HEPATOLOGY, 33, 1353, 10.1053/jhep.2001.25087

Taylar-Robinson, 2001, Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998, Gut, 48, 816, 10.1136/gut.48.6.816

Khan, 2005, Cholangiocarcinoma, Lancet, 366, 1303, 10.1016/S0140-6736(05)67530-7

Mosconi, 2009, Cholangiocarcinoma, Crit Rev Oncol Hematol, 69, 259, 10.1016/j.critrevonc.2008.09.008

Khan, 2002, Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document, Gut, 51, VI1, 10.1136/gut.51.suppl_6.vi1

Koopmann, 2004, Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma, Cancer, 101, 1609, 10.1002/cncr.20469

Chen, 2002, The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma-the influence of sampling time and hepatolithiasis, Hepatogastroenterology, 49, 616

Ker, 1991, Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma, J Gastroenterol Hepatol, 6, 505, 10.1111/j.1440-1746.1991.tb00896.x

Sauri, 1990, Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures, HEPATOLOGY, 12, 747, 10.1002/hep.1840120421

Kurzawinski, 1992, A prospective controlled study comparing brush and bile exfoliative cytology for diagnosing bile duct strictures, Gut, 33, 1675, 10.1136/gut.33.12.1675

Kurzawinski, 1993, A prospective study of biliary cytology in 100 patients with bile duct strictures, HEPATOLOGY, 18, 1399, 10.1002/hep.1840180618

Hakomori, 2002, Glycosylation defining cancer malignancy: new wine in an old bottle, Proc Natl Acad Sci U S A, 99, 10231, 10.1073/pnas.172380699

Fukuda, 1996, Possible roles of tumor-associated carbohydrate antigens, Cancer Res, 56, 2237

Taketa, 1990, Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions, Gastroenterology, 99, 508, 10.1016/0016-5085(90)91034-4

Nakagawa, 2008, Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients, J Proteome Res, 7, 2222, 10.1021/pr700841q

Ito, 2009, Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools, J Proteome Res, 8, 1358, 10.1021/pr800735j

Hirabayashi, 2008, Concept, strategy and realization of lectin-based glycan profiling, J Biochem, 144, 139, 10.1093/jb/mvn043

Kuno, 2005, Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling, Nat Methods, 2, 851, 10.1038/nmeth803

Uchiyama, 2008, Optimization of evanescent-field fluorescence-assisted lectin microarray for high-sensitivity detection of monovalent oligosaccharides and glycoproteins, Proteomics, 8, 3042, 10.1002/pmic.200701114

Matsuda, 2008, Development of an all-in-one technology for glycan profiling targeting formalin-embedded tissue sections, Biochem Biophys Res Commun, 370, 259, 10.1016/j.bbrc.2008.03.090

Brockhausen, 1999, Pathways of O-glycan biosynthesis in cancer cells, Biochim Biophys Acta, 1473, 67, 10.1016/S0304-4165(99)00170-1

Kuno, 2008, Development of a data-mining system for differential profiling of cell glycoproteins based on lectin microarray, J Proteomics Bioinform, 1, 061, 10.4172/jpb.1000011

Zweig, 1993, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine, Clin Chem, 39, 561, 10.1093/clinchem/39.4.561

Yamamoto, 1996, A novel monoclonal antibody specific for sialylated MUC1 mucin, Jpn J Cancer Res, 87, 488, 10.1111/j.1349-7006.1996.tb00250.x

Takeuchi, 2002, The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat, J Immunol Methods, 270, 199, 10.1016/S0022-1759(02)00298-3

Nakagawa, 2006, Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts, J Biol Chem, 281, 29797, 10.1074/jbc.M605697200

Yamazaki, 1988, Biliary proteins: assessment of quantitative techniques and comparison in gallstone and nongallstone subjects, J Lipid Res, 29, 1055, 10.1016/S0022-2275(20)38469-8

Kuno, 2009, Focused differential glycan analysis with the platform antibody-assisted lectin profiling (ALP) for glycan-related biomarker verification, Mol Cell Proteomics, 8, 99, 10.1074/mcp.M800308-MCP200

Ikehara, 2006, Apical Golgi localization of N,N′-diacetyllactosediamine synthase, β4GalNAc-T3, is responsible for LacdiNAc expression on gastric mucosa, Glycobiology, 16, 777, 10.1093/glycob/cwl005

Kawamoto, 2001, Expression of MUC1 mucins in the subserosal layer correlates with post-surgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder, Clin Cancer Res, 7, 1333

Higashi, 1999, Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma, HEPATOLOGY, 30, 1347, 10.1002/hep.510300609

Bamrungphon, 2007, A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma, Cancer Lett, 247, 301, 10.1016/j.canlet.2006.05.007

Narimatsu, 2010, A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics, FEBS J, 277, 95, 10.1111/j.1742-4658.2009.07430.x

Matsuzaki, 1994, A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma, Gastroenterology, 106, 1032, 10.1016/0016-5085(94)90764-1

Chiba, 2005, Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients, Clin Cancer Res, 11, 3799, 10.1158/1078-0432.CCR-04-1350

Maeda, 1995, Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analyses of clinicopathologic features, Hum Pathol, 26, 956, 10.1016/0046-8177(95)90084-5

Johnson, 1988, The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma, Am J Surg Pathol, 12, 187, 10.1097/00000478-198803000-00004

Yamashita, 2008, EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma, Cancer Res, 68, 1451, 10.1158/0008-5472.CAN-07-6013

Yamashita, 2009, EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features, Gastroenterology, 136, 1012, 10.1053/j.gastro.2008.12.004

Nishino, 2008, Identification of novel candidate tumor marker genes for intrahepatic cholangiocarcinoma, J Hepatol, 49, 207, 10.1016/j.jhep.2008.03.025